Illumina Earnings Call Highlights NovaSeq-Fueled Rebound

Illumina ((ILMN)) has held its Q1 earnings call. Read on for the main highlights of the call.

Illumina’s latest earnings call struck an upbeat tone as management highlighted a clean top- and bottom-line beat, expanding margins, and strong clinical sequencing momentum while framing pockets of weakness as cyclical or manageable. The overall message was one of controlled optimism, with confidence in the long-term plan even as near-term research demand and inflation remain headwinds.

Top-Line Beat and Higher Full-Year Targets

Illumina delivered Q1 revenue of $1.09 billion, up 4.8% year over year and about $20 million above the midpoint of guidance, demonstrating solid execution. Management responded by lifting the 2026 revenue outlook to a range of $4.52 billion to $4.62 billion and nudging both EPS and margin guidance higher, signaling faith in sustained improvement.

Clinical Consumables Drive Sequencing Growth

Sequencing consumables revenue reached $726 million, growing 4% from a year ago with Rest of World organic growth around 5%, underpinned by clinical demand. Clinical consumables again grew about 20% excluding China and now represent more than 65% of sequencing consumables, underscoring a mix shift toward higher-value, more resilient healthcare usage.

NovaSeq X Transition Accelerates Installed Base

The company placed more than 80 NovaSeq X instruments in Q1, roughly 20 more than in the prior-year period, and is rapidly moving volume to the new platform. About 82% of sequencing volumes and 55% of revenue are now on NovaSeq X, with 90% of research and 76% of clinical throughput already transitioned and a target of 80% to 85% clinical by late 2026.

Throughput Expansion and Instrument Momentum

Total sequencing output on connected high- and mid-throughput systems jumped more than 30% versus last year, showing customers are pushing installed instruments harder. Sequencing instrument revenue grew 9% to $118 million, with Rest of World organic instrument sales up about 10%, supporting the view that hardware demand remains healthy despite macro uncertainty.

Margins Widen and EPS Surprises to the Upside

Non-GAAP gross margin improved to 68.2%, roughly 80 basis points better than a year ago, while non-GAAP operating margin expanded about 150 basis points to 21.9%. That operating leverage helped deliver non-GAAP EPS of $1.15, up about 19% year on year and roughly $0.10 above the guidance midpoint, prompting a higher full-year margin target of 23.4% to 23.6%.

Robust Cash Generation and Shareholder Returns

Operating cash flow reached $289 million and free cash flow came in at $251 million in Q1, giving Illumina ample flexibility for capital deployment. The company repurchased 2 million shares for $242 million and secured board approval for an additional $1.5 billion buyback program, while ending the quarter with around $1.16 billion in cash and modest gross leverage of about 1.5 times.

Strategic Deals and a Busy Innovation Pipeline

Illumina closed its acquisition of SomaLogic with a net cash outlay near $363 million and said the integration is tracking in line with expectations, enhancing its proteomics and multi-omics capabilities. On the product front, management highlighted the TruePath workflow for faster whole-genome prep, plans for spatial transcriptomics, an 18-month NovaSeq X roadmap with higher-density flow cells, and data initiatives such as BioInsight and a large-scale cell atlas.

Long-Term Growth Path Reaffirmed

Despite only a modest tweak to this year’s revenue outlook, management reiterated a path to high single-digit revenue growth as adoption of clinical sequencing and new technologies builds. The company is targeting roughly 350 basis points of margin expansion by the end of 2026 excluding acquisitions, supporting expectations for double-digit to mid-teens EPS growth on the way toward its 2027 goals.

Research and Applied Consumables Under Pressure

Not all end markets are firing, as sequencing consumables for research and applied customers declined 12% excluding China in the quarter, reflecting funding uncertainty and cautious lab spending. Illumina continues to guide this segment down by a mid- to high-single-digit rate for the full year, tempering overall organic growth even as clinical demand remains strong.

Microarrays Face a Steep Decline

The legacy microarrays business weighed on results, with revenue down 20% on a Rest of World organic basis primarily because of softness at a few large direct-to-consumer customers. Management framed this as a structural headwind that will remain a drag, though increasingly smaller relative to the faster-growing sequencing franchise.

NovaSeq X Demand Outpaces Current Supply

Illumina is actually supply constrained on NovaSeq X systems, with demand running above its targeted placement range of 50 to 60 instruments per quarter, forcing the company to invest in capacity. That dynamic can delay some revenue recognition on instruments and adds near-term complexity but is essentially a “good problem” that underscores the platform’s strong market reception.

Near-Term Margin Headwinds From Mix and Inflation

The company’s Q2 outlook assumes a lower operating margin of around 22%, as a higher mix of instruments, inflation in freight and electronic components, and a full-quarter impact from SomaLogic weigh on profitability. Management expects cost actions and mix shift to offset these pressures over the back half of the year, with margins improving as volumes and efficiencies ramp.

Conservative Growth Outlook After a Strong Quarter

Despite the Q1 beat and clear strength in clinical and instruments, Illumina only lifted reported revenue by $20 million and kept organic growth assumptions relatively tight, reflecting a cautious stance. Executives noted that it remains early in the year and that research funding and broader macro conditions are still uncertain, warranting prudence rather than aggressive guidance.

Complexities in Instrument Revenue Recognition

Management also highlighted that some NovaSeq deals use reagent rental or lease models and multi-unit volume discounts, which shift economics toward future consumables rather than up-front instrument revenue. This structure can make quarter-to-quarter instrument revenue less comparable and explains why reported hardware sales may lag visible placement metrics in some periods.

Guidance and Outlook Signal Confidence With Caution

Looking ahead, Illumina raised its 2026 revenue outlook to $4.52 billion to $4.62 billion, with acquisitions and currency adding modest tailwinds and Rest of World organic growth expected toward the high end of 2% to 4%. For the near term, Q2 revenue is guided to $1.12 billion to $1.14 billion with non-GAAP EPS of $1.20 to $1.25, and full-year profitability targets now call for a 23.4% to 23.6% operating margin and non-GAAP EPS of $5.15 to $5.30, underpinned by continued NovaSeq X adoption and cost discipline.

Illumina’s earnings call painted a picture of a company back on the front foot, with clinical sequencing and NovaSeq X adoption powering growth, margins moving up, and cash returns to shareholders accelerating. While weaker research demand, microarray erosion, and near-term cost pressures temper the story, management’s balanced guidance and clear progress toward 2027 targets should reassure investors focused on the long-term trajectory of the franchise.